Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with
significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an …

The progress in aplastic anaemia (AA) management is one of success. Once an obscure
entity resulting in death in most affected can now be successfully treated with either …

Paroxysmal nocturnal haemoglobinuria (PNH) clones are frequently detected in patients
with aplastic anaemia (AA). To evaluate the prognostic role of PNH clone presence we …

The current treatment approach for severe aplastic anemia in children is based on studies
performed in the 1980s, and updated evidence is required. We retrospectively compared the …

Pretreatment blood counts, particularly an absolute reticulocyte count≥ 25× 10 9/L,
correlate with response to immunosuppressive therapy in severe aplastic anemia. In recent …

Background A combination of horse anti-thymocyte globulin and cyclosporine produces
responses in 60–70% of patients with severe aplastic anemia. We performed a phase II …

Acquired aplastic anemia is an immune-mediated disease characterized by severe defects
in stem cell number resulting in hypocellular marrow and peripheral blood cytopenias. Minor …

Background: Antihuman T lymphocyte porcine immunoglobulin (p-ATG) has been the most
common ATG preparation in immunosuppressive therapy (IST) in Chinese patients with …

Abstract Purpose of Review This review aimed to provide updated guidelines for the
management of children with acquired aplastic anemia (AA), particularly focusing on …

In aplastic anemia, predictive markers of response to immunosuppressive therapy have not
been well defined. We retrospectively evaluated whether clinical and laboratory findings …